Entyvio Market Report 2026

Entyvio Market Overview

• The Entyvio market growth in the historic period has been driven by limitations of conventional immunosuppressive therapies, rising incidence of inflammatory bowel disease • Market expansion is supported by increasing global ibd prevalence, expansion into earlier treatment lines • Growth Driver: Rising Incidence Of Inflammatory Bowel Disease Fuels Growth Of The Entyvio Market • Market Trend: Takeda’s Focus on Maintenance Therapies Drives Entyvio’s Long-Term Effectiveness in Crohn’s Disease Management • North America was the largest region in 2025 and Asia-Pacific is the fastest growing region.

What Is Covered Under Entyvio Market?

Entyvio (vedolizumab) is a monoclonal antibody medication. It functions as an integrin receptor antagonist, targeting and blocking the movement of inflammatory white blood cells into the gastrointestinal tract, thereby reducing inflammation and helping to control symptoms associated with these conditions. The main routes of administration in Entyvio market are subcutaneous injection and intravenous infusion. Subcutaneous injection of Entyvio (vedolizumab) refers to a formulation of the drug that allows patients to administer the treatment at home. The various treatment lines include first-line therapy and second-line therapy, and several indications including ulcerative colitis (UC) and Crohn's disease (CD). These are used by various end users such as hospitals, clinics, ambulatory care, and home care.

What Is The Entyvio Market Growth Forecast?

The growth in the forecast period can be attributed to increasing global ibd prevalence, expansion into earlier treatment lines, improved diagnostic rates, growing biologic therapy access, long term disease management focus. Major trends in the forecast period include rising use of gut selective biologic therapies, growing adoption in moderate to severe ibd, increased preference for targeted integrin inhibition, expansion of long term maintenance therapy use, improved safety focus compared to systemic immunosuppressants.

What Are The Drivers Of The Entyvio Market?

The increasing incidence of inflammatory bowel disease is expected to propel the growth of the entyvio market going forward. Inflammatory bowel disease (IBD) is a group of chronic, relapsing inflammatory disorders of the gastrointestinal (GI) tract, characterized by immune system dysregulation, leading to prolonged inflammation and tissue damages. The increasing incidence of inflammatory bowel disease is due to a combination of genetic predisposition, environmental factors such as diet and urbanization, lifestyle changes including higher stress levels, and alterations in gut microbiota driven by factors such as antibiotic use and reduced exposure to natural microbes. Entyvio helps in treating inflammatory bowel disease (IBD) by targeting and blocking the alpha4beta7 integrin, which reduces the migration of inflammatory cells to the gut. For instance, in June 2024, according to the Centre for Disease Control and Prevention, a US- based non-profit organization, estimates that the prevalence of inflammatory bowel disease (IBD) in the United States ranges from 2.4 to 3.1 million people. Therefore, increasing prevalence of inflammatory bowel disease is driving the growth of the entyvio industry. Rise in healthcare expenditure is expected to propel the growth of the entyvio market going forward. Healthcare expenditure refers to the total financial resources spent on health services and goods to maintain or improve the health of individuals and populations. The rising healthcare expenditure is due to factors such as the growing prevalence of chronic diseases, advancements in medical technology, an aging population requiring more intensive care, increased costs of prescription drugs and specialized treatments, and expanding access to healthcare services in both developed and developing regions. Healthcare expenditure supports entyvio by facilitating access to advanced biologic therapies for patients with inflammatory bowel diseases such as Crohn's disease and ulcerative colitis, ensuring funding for its research, development, distribution, and integration into treatment protocols while promoting improved patient outcomes and healthcare system efficiency. For instance, in May 2023, according to a report published by the Office for National Statistics, a UK-based government department, between 2022 and 2023, healthcare spending in the UK increased by 5.6% compared with growth of 0.9% in 2022. The UK healthcare expenditure in UK healthcare expenditure was around $317.63 billion (£292 billion) in 2023. Therefore, rise in healthcare expenditure is driving the growth of the entyvio industry.

Key Players In The Global Entyvio Market

Major companies operating in the entyvio market are Takeda Pharmaceutical Company Limited

Global Entyvio Market Trends and Insights

Major companies operating in the entyvio market are focusing on developing maintenance therapies to improve the long-term management of inflammatory bowel disease (IBD). Maintenance therapies refer to ongoing treatments designed to manage chronic conditions, prevent disease progression, and sustain a stable or improved state of health after achieving initial therapeutic goals. These therapies aim to reduce the risk of relapses, complications, or symptoms over time, ensuring long-term disease control and improved quality of life for patients. For instance, in April 2024, Takeda pharmaceutical, a US based pharmaceutical company, received Food and Drug Administration, a US-based federal agency, approval for the subcutaneous (SC) administration for maintenance therapy in adults with moderately to severely active Crohn’s disease (CD) after induction therapy with intravenous (IV) Entyvio. The subcutaneous option allows for self-administration using a pre-filled pen, making it more convenient for patients to manage their treatment at home after an initial IV infusion during the induction phase. Clinical studies have shown that Entyvio significantly improves symptoms and induces remission in patients with Crohn's disease compared to placebo.

What Defines the Entyvio Market?

The entyvio market consists of sales of induction therapy and maintenance therapy. Values in this market are ‘factory gate’ values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

How is Market Value Defined and Measured?

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified). The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

What Key Data and Analysis Are Included in the Entyvio Market Report 2026?

The entyvio market research report is one of a series of new reports from The Business Research Company that provides market statistics, including industry global market size, regional shares, competitors with the market share, detailed market segments, market trends and opportunities, and any further data you may need to thrive in the entyvio industry. The market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future state of the industry.